HaiHe Biopharma Co., Ltd is a biopharmaceutical company focusing on discovery, development and commercialization of innovative anti-tumor drugs.Guided by their mission, “Inclusive and open to diversity, innovation oriented to win together and benefit the mankind”, HaiHe Biopharma insists on the way of independent innovation and pursues for global development of Chinese original innovative drugs in partnership with Shanghai Institute of Materia Medica, Chinese Academy of Science (SIMM).In March 2018, Shanghai HaiHe Pharmaceutical Co., Ltd. merged with RMX (Shanghai) Pharmaceutical Technology Co., Ltd. The company is led by an academician of the Chinese Academy of Engineering and a National Thousand Talent. The senior management team has extensive experiences in drug research and development in China and abroad. Over the past years, HaiHe Biopharma has built fully integrated pre-clinical evaluation technical platform and clinical study system for innovative drugs, with advanced technology and operation in consistence with international standards and norms, covering subunits from compound synthesis, quality study, formulation development, pharmacological and pharmacodynamics evaluation, biomarker discovery and validation, medical strategy and clinical study, etc. The company has established a globally competitive innovative drug R&D system and robust product pipeline. There are 10 compounds in clinical and 5 compounds in preclinical studies, among which 9 compounds are discovered in-house.Number of Partnerships: 10
